Armata Pharmaceuticals, Inc.
ARMP
$9.00
$0.182.04%
AMEX
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -12.15% | -61.02% | -- | -49.17% | -19.18% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -12.15% | -61.02% | -- | -49.17% | -19.18% |
| Cost of Revenue | -3,884.31% | -38.60% | -48.30% | -32.27% | -99.36% |
| Gross Profit | 154.65% | 28.36% | 719.81% | 29.96% | 118.50% |
| SG&A Expenses | -2.53% | -4.10% | -23.84% | 2.36% | 268.76% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.35% | -29.81% | -24.35% | -22.44% | 6.01% |
| Operating Income | 20.19% | 20.30% | 42.55% | 19.92% | -10.02% |
| Income Before Tax | -4,880.69% | -386.68% | -281.34% | 73.90% | 113.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4,880.69% | -386.68% | -281.34% | 73.90% | 113.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4,880.69% | -386.68% | -281.34% | 73.90% | 113.10% |
| EBIT | 20.19% | 20.30% | 42.55% | 19.92% | -10.02% |
| EBITDA | 21.32% | 21.57% | 44.15% | 21.16% | -9.40% |
| EPS Basic | -4,855.63% | -386.01% | -281.17% | 73.94% | 113.08% |
| Normalized Basic EPS | 4.65% | 2.95% | 26.90% | 2.31% | -24.60% |
| EPS Diluted | -553.20% | -386.01% | -81.97% | 71.51% | 4.67% |
| Normalized Diluted EPS | -55.73% | 2.95% | -17.79% | 40.58% | 23.71% |
| Average Basic Shares Outstanding | 0.47% | 0.13% | 0.11% | 0.17% | 0.23% |
| Average Diluted Shares Outstanding | -38.47% | 0.13% | -37.86% | 64.65% | 63.66% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |